Completed PHASE1 INTERVENTIONAL 3-arm NCT02657161

Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Sponsor: Duke-NUS Graduate Medical School

Conditions Rabies

Interventions PIKA rabies vaccine PIKA rabies vaccine with an accelerated regimen RABIPUR®

Updated 6 times since 2017 Last updated: Jan 13, 2016 Started: Feb 28, 2015 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Rabies, this trial is completed. The trial is conducted by Duke-NUS Graduate Medical School and has accumulated 6 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duke-NUS Graduate Medical School
Yisheng Biopharma (Singapore) Pte. Ltd.

Data source: Yisheng Biopharma (Singapore) Pte. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore